Several preclinical and clinical studies have shown that therapy with plasma purified AAT is not only beneficial for emphysema patients with inherited AAT deficiency, but also useful for other inflammatory and immune-mediated conditions [14]. The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.